Literature DB >> 19351437

CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases.

Cynthia A Zahnow1.   

Abstract

The CCAAT/enhancer-binding proteins (C/EBPs) are a family of leucine-zipper transcription factors that regulate gene expression to control cellular proliferation, differentiation, inflammation and metabolism. Encoded by an intronless gene, C/EBPbeta is expressed as several distinct protein isoforms (LAP1, LAP2, LIP) whose expression is regulated by the differential use of several in-frame translation start sites. LAP1 and LAP2 are transcriptional activators and are associated with differentiation, whereas LIP is frequently elevated in proliferative tissue and acts as a dominant-negative inhibitor of transcription. However, emerging evidence suggests that LIP can serve as a transcriptional activator in some cellular contexts, and that LAP1 and LAP2 might also have unique actions. The LIP:LAP ratio is crucial for the maintenance of normal growth and development, and increases in this ratio lead to aggressive forms of breast cancer. This review discusses the regulation of C/EBPbeta activity by post-translational modification, the individual actions of LAP1, LAP2 and LIP, and the functions and downstream targets that are unique to each isoform. The role of the C/EBPbeta isoforms in breast cancer is discussed and emphasis is placed on their interactions with receptor tyrosine kinases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19351437      PMCID: PMC3095491          DOI: 10.1017/S1462399409001033

Source DB:  PubMed          Journal:  Expert Rev Mol Med        ISSN: 1462-3994            Impact factor:   5.600


  201 in total

1.  Mice with a deletion in the gene for CCAAT/enhancer-binding protein beta have an attenuated response to cAMP and impaired carbohydrate metabolism.

Authors:  C M Croniger; C Millward; J Yang; Y Kawai; I J Arinze; S Liu; M Harada-Shiba; K Chakravarty; J E Friedman; V Poli; R W Hanson
Journal:  J Biol Chem       Date:  2001-01-05       Impact factor: 5.157

2.  Overexpression of C/EBPbeta-LIP, a naturally occurring, dominant-negative transcription factor, in human breast cancer.

Authors:  C A Zahnow; P Younes; R Laucirica; J M Rosen
Journal:  J Natl Cancer Inst       Date:  1997-12-17       Impact factor: 13.506

3.  Magnesium is required for specific DNA binding of the CREB B-ZIP domain.

Authors:  Jonathan R Moll; Asha Acharya; Jozsef Gal; Alain A Mir; Charles Vinson; Jozset Gal
Journal:  Nucleic Acids Res       Date:  2002-03-01       Impact factor: 16.971

Review 4.  Molecular stop signs: regulation of cell-cycle arrest by C/EBP transcription factors.

Authors:  Peter F Johnson
Journal:  J Cell Sci       Date:  2005-06-15       Impact factor: 5.285

5.  Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas.

Authors:  Vassiliki Theodorou; Mandy Boer; Britta Weigelt; Jos Jonkers; Martin van der Valk; John Hilkens
Journal:  Oncogene       Date:  2004-08-12       Impact factor: 9.867

6.  EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease.

Authors:  Maria Vittoria Arcidiacono; Tetsuhiko Sato; Daniel Alvarez-Hernandez; Jing Yang; Masanori Tokumoto; Ignacio Gonzalez-Suarez; Yan Lu; Yoshihiro Tominaga; Jorge Cannata-Andia; Eduardo Slatopolsky; Adriana S Dusso
Journal:  J Am Soc Nephrol       Date:  2008-01-23       Impact factor: 10.121

7.  Stromal gene expression predicts clinical outcome in breast cancer.

Authors:  Greg Finak; Nicholas Bertos; Francois Pepin; Svetlana Sadekova; Margarita Souleimanova; Hong Zhao; Haiying Chen; Gulbeyaz Omeroglu; Sarkis Meterissian; Atilla Omeroglu; Michael Hallett; Morag Park
Journal:  Nat Med       Date:  2008-04-27       Impact factor: 53.440

Review 8.  The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control.

Authors:  Claus Nerlov
Journal:  Trends Cell Biol       Date:  2007-07-19       Impact factor: 20.808

9.  Differential control of the CCAAT/enhancer-binding protein beta (C/EBPbeta) products liver-enriched transcriptional activating protein (LAP) and liver-enriched transcriptional inhibitory protein (LIP) and the regulation of gene expression during the response to endoplasmic reticulum stress.

Authors:  Yi Li; Elena Bevilacqua; Calin-Bogdan Chiribau; Mithu Majumder; Chuanping Wang; Colleen M Croniger; Martin D Snider; Peter F Johnson; Maria Hatzoglou
Journal:  J Biol Chem       Date:  2008-06-11       Impact factor: 5.157

10.  Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors.

Authors:  F Czubayko; R V Smith; H C Chung; A Wellstein
Journal:  J Biol Chem       Date:  1994-11-11       Impact factor: 5.157

View more
  78 in total

1.  CCAAT/Enhancer-binding protein beta DNA binding is auto-inhibited by multiple elements that also mediate association with p300/CREB-binding protein (CBP).

Authors:  Sook Lee; Maria Miller; Jon D Shuman; Peter F Johnson
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

2.  Blockade of adipocyte differentiation by cordycepin.

Authors:  Shuhei Takahashi; Minori Tamai; Shotaro Nakajima; Hironori Kato; Hisashi Johno; Tomoyuki Nakamura; Masanori Kitamura
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

3.  C/EBPγ suppresses senescence and inflammatory gene expression by heterodimerizing with C/EBPβ.

Authors:  Christopher J Huggins; Radek Malik; Sook Lee; Jacqueline Salotti; Sara Thomas; Nancy Martin; Octavio A Quiñones; W Gregory Alvord; Mary E Olanich; Jonathan R Keller; Peter F Johnson
Journal:  Mol Cell Biol       Date:  2013-06-17       Impact factor: 4.272

4.  Molecular symbiosis of CHOP and C/EBP beta isoform LIP contributes to endoplasmic reticulum stress-induced apoptosis.

Authors:  Calin-Bogdan Chiribau; Francesca Gaccioli; Charlie C Huang; Celvie L Yuan; Maria Hatzoglou
Journal:  Mol Cell Biol       Date:  2010-05-17       Impact factor: 4.272

5.  C/EBPα, C/EBPα oncoproteins, or C/EBPβ preferentially bind NF-κB p50 compared with p65, focusing therapeutic targeting on the C/EBP:p50 interaction.

Authors:  Julia E Dooher; Ido Paz-Priel; Simone Houng; Albert S Baldwin; Alan D Friedman
Journal:  Mol Cancer Res       Date:  2011-08-03       Impact factor: 5.852

6.  Crosstalk between phosphorylation and multi-site arginine/lysine methylation in C/EBPs.

Authors:  Achim Leutz; Ole Pless; Michael Lappe; Gunnar Dittmar; Elisabeth Kowenz-Leutz
Journal:  Transcription       Date:  2011 Jan-Feb

7.  Molecular alterations associated with chronic exposure to cigarette smoke and chewing tobacco in normal oral keratinocytes.

Authors:  Pavithra Rajagopalan; Krishna Patel; Ankit P Jain; Vishalakshi Nanjappa; Keshava K Datta; Tejaswini Subbannayya; Kiran K Mangalaparthi; Anjali Kumari; Malini Manoharan; Karunakaran Coral; Sakthivel Murugan; Bipin Nair; T S Keshava Prasad; Premendu P Mathur; Ravi Gupta; Rohit Gupta; Arati Khanna-Gupta; Joseph Califano; David Sidransky; Harsha Gowda; Aditi Chatterjee
Journal:  Cancer Biol Ther       Date:  2018-05-29       Impact factor: 4.742

8.  Production of a monoclonal antibody for C/EBPβ: the subnuclear localization of C/EBPβ in mouse L929 cells.

Authors:  Akihito Harada; Etsuko Okazaki; Seiji Okada; Taro Tachibana; Yasuyuki Ohkawa
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2014-02

9.  C/EBP β mRNA expression is upregulated and positively correlated with the expression of TNIP1/TNFAIP3 in peripheral blood mononuclear cells from patients with systemic lupus erythematosus.

Authors:  Tian Qian; Yan Chen; Xiaowei Shi; Jian Li; Fei Hao; Dongmei Zhang
Journal:  Exp Ther Med       Date:  2016-08-23       Impact factor: 2.447

10.  Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk.

Authors:  Tiva T VanCleave; Jason H Moore; Marnita L Benford; Guy N Brock; Ted Kalbfleisch; Richard N Baumgartner; James W Lillard; Rick A Kittles; La Creis R Kidd
Journal:  Prostate       Date:  2010-03-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.